Sjögren-Larsson syndrome

Sjögren-Larsson syndrome (SLS) is a hereditary disorder characterized by a combinatorial defect of the sebaceous glands, manifested as keratoses, changes in skin pigmentation and neurological disorders. The disease belongs to a group of skin disorders caused by metabolic disorders and is associated with abnormalities in fatty acid metabolism. The underlying pathological process involves a disruption in the formation of complex lipids, which leads to systemic manifestations, including dry skin, itching and increased sensitivity to external stimuli. The age of onset of the syndrome varies, but, as a rule, the first clinical manifestations occur in childhood or adolescence. One of the key features of the disease is its hereditary nature, associated with the mutation of certain genes, which makes it an important area of research in genetic medicine.

History of the disease and interesting historical facts

Sjogren-Larsson syndrome was first described in 1965 by Swedish dermatologist Erik Sjogren and ophthalmologist Larsson. Based on the analysis of observations, scientists noted a connection between clinical symptoms and heredity. Since then, the syndrome has attracted the attention of researchers, and in 1971, the first molecular data on the genetic mutations responsible for the development of the disease were recorded. Interestingly, over the following years, extensive definitions and divisions between various forms of keratosis were carried out, which contributed to a deeper understanding of the pathogenesis. Finally, in recent decades, the history of the syndrome has been supplemented by numerous geno-epidemiological studies, which allows us to better understand its prevalence and genetic mechanisms.

Epidemiology

The epidemiology of Sjögren-Larsson syndrome varies across geographic and ethnic groups. In Europeans, the incidence is approximately 1 in 100,000, but in some northern regions it may be as high as 1 in 50,000. This difference is due to certain population conditions and increased inbreeding in small communities. In addition, the study found that the syndrome is more common in families with a history of skin diseases, indicating a hereditary nature of the pathology. To date, relatively few epidemiological studies have been conducted outside Europe, making it necessary to further study the syndrome in an international framework.

Genetic predisposition to this disease

Genetic predisposition to Sjögren-Larsson syndrome is associated with mutations in the ELOVL3 gene, which is responsible for the synthesis of long-chain saturated and unsaturated fatty acids. This gene is localized on chromosome 2 and is key to normal lipid metabolism. In particular, mutations in this gene lead to a disruption in the formation of cerbosides, which in turn are important components for the functioning of cell membranes. More than 30 different mutations associated with the syndrome have been identified, and each of them can manifest itself with varying severity of clinical symptoms. Genetic testing can also identify mutation carriers in families with abnormal cases, which allows for genetic counseling to prevent the disease.

Risk factors for the development of this disease

Risk factors that contribute to the development of Sjogren-Larsson syndrome include:

• Hereditary predisposition - having first-degree relatives with this syndrome significantly increases the risk of the disease in offspring.
• Genetic mutations - mutations in genes involved in fatty acid metabolism increase the likelihood of developing the syndrome.
• Environmental conditions - exposure to certain chemicals may worsen symptoms in susceptible individuals.
• Skin microbiota issues - microbiome imbalances may be associated with more severe symptoms in those with the syndrome.

The syndromic nature of this disease makes it necessary to take a comprehensive approach to studying these factors.

Diagnosis of this disease

Diagnosis of Sjogren-Larsson syndrome is based on a combination of clinical manifestations and laboratory tests. The main symptoms to look out for include:

• Keratosis is a visible change in the skin that can appear as psoriasis-like plaques.
• Pigmentation - characteristic hyperpigmentation in the area of the elbows and knees.
• It is important to consider the presence of neurological impairments, such as difficulties with coordination and sensation.

Laboratory tests may include a lipid profile and testing for mutations in the ELOVL3 gene. Radiologic tests, such as MRI, may be needed to detect neurologic symptoms. Differential diagnoses include diffuse dermatoses, other genetic skin diseases, and metabolic syndromes.

Treatment

Treatment for Sjogren-Larsson syndrome requires an individualized approach and may include:

• General treatment involves improving skin care and eating a diet rich in omega-3 fatty acids.
• Pharmacological treatment - use of retinoids and corticosteroids to manage skin manifestations.
• Surgical treatment - in rare cases, surgical interventions may be recommended to correct specific problems.
• Other treatments - including physical therapy to improve neurological impairment.

The effectiveness of treatment depends on the timeliness of contacting specialists and following recommendations.

List of medications used to treat this disease

Medications used to treat Sjogren-Larsson syndrome include:

• Tretinoin - for topical use in keratoses.
• Dexpanthenol - for moisturizing and healing the skin.
• Milastin is a drug for normalizing metabolism in the skin.
• Corticosteroids - to reduce inflammation.
• Physiotherapeutic agents – improve microcirculation and relax the skin.

This group of drugs is prescribed by a doctor depending on the nature of the changes.

Disease monitoring

Monitoring Sjögren-Larsson syndrome requires regular check-ups, including:

• Evaluation of the dynamics of skin condition and neurological symptoms on a regular basis.
• Laboratory tests to monitor changes in lipid profile.
• Psychological support for patients with neurological manifestations and impaired quality of life.

The prognosis depends on the severity of the disease, but with timely treatment and adherence to treatment recommendations, many patients can experience significant improvement.

Age-related features of the disease

Sjogren-Larsson syndrome has different age-related features of manifestation. In childhood, the disease may manifest itself more acutely, while in adults, manifestations may be less noticeable, but more persistent. In older people, as a rule, there is a deterioration in the condition due to concomitant diseases and less pronounced adaptive mechanisms of the body. Based on this, individual treatment regimens should be developed taking into account the patient's age category.

Questions and Answers

• What are the main symptoms of Sjogren-Larsson syndrome? The main symptoms include keratosis, hyperpigmentation, neurological disorders and dry skin.
• What diagnostic methods are used for the syndrome? Diagnosis includes a clinical examination, genetic testing, and laboratory blood tests to assess the lipid profile.
• What treatment is indicated for this syndrome? Treatment may include retinoids, corticosteroids, and improved skin care.
• How common is this disease? The incidence of the syndrome ranges from 1 in 100,000 to 1 in 50,000 depending on the population.
• Are there any specific features in the course of the disease at different ages? Yes, in childhood the manifestations may be more acute, while in adults they may be less pronounced, but chronic.